Cargando…

Pharmacokinetics, Safety and Pharmacokinetics/Pharmacodynamics Analysis of Omadacycline in Chinese Healthy Subjects

Objective: Omadacycline is a new type of aminomethylcycline antibiotic, having a broad antibacterial spectrum. But the pharmacokinetic characteristics and safety profile of the Chinese population remain unknown. It is also unclear whether the US-approved treatment regimen is applicable for the Chine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Haijing, Huang, Zhiwei, Chen, Yuancheng, Zhu, Yusong, Cao, Guoying, Wang, Jingjing, Guo, Yan, Yu, Jicheng, Wu, Jufang, Liu, Lichuan, Deng, Jun, Liu, Jing, Reinhart, Harald, Zhang, Jing, Wu, Xiaojie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9068897/ https://www.ncbi.nlm.nih.gov/pubmed/35529438 http://dx.doi.org/10.3389/fphar.2022.869237

Ejemplares similares

Pharmacokinetic, Pharmacokinetic/Pharmacodynamic, and Safety Investigations of Lefamulin in Healthy Chinese Subjects
por: Hu, Yingying, et al.
Publicado: (2023)

Pharmacokinetics of Levornidazole Tablet in Healthy Chinese Subjects and Proposed Dosing Regimen Based on Pharmacokinetic/Pharmacodynamic Analysis
por: Wu, Hailan, et al.
Publicado: (2021)

Integrative population pharmacokinetic/pharmacodynamic analysis of nemonoxacin capsule in Chinese patients with community-acquired pneumonia
por: Chen, Yuancheng, et al.
Publicado: (2023)

LZM008, a proposed tocilizumab biosimilar: Pharmacokinetics, safety, and immunogenicity profiles compared with ACTEMRA(®) in Chinese healthy male subjects
por: Cao, Guoying, et al.
Publicado: (2023)

Pharmacokinetics and Pharmacodynamics of Colistin Methanesulfonate in Healthy Chinese Subjects after Multi-Dose Regimen
por: Fan, Yaxin, et al.
Publicado: (2022)

Pharmacokinetics and Safety of Omadacycline in Subjects with Impaired Renal Function
por: Berg, Jolene K., et al.
Publicado: (2018)

Pharmacokinetics and Pharmacodynamics of Oral and Intravenous Omadacycline
por: Rodvold, Keith A, et al.
Publicado: (2019)

Population Pharmacokinetics and Dosing Regimen Optimization of Meropenem in Cerebrospinal Fluid and Plasma in Patients with Meningitis after Neurosurgery
por: Lu, Cheng, et al.
Publicado: (2016)

Evaluation of the Impact of Comorbidities on Omadacycline Pharmacokinetics
por: Trang, M., et al.
Publicado: (2023)

A phase I study of the safety, tolerability, and pharmacokinetics of contezolid acefosamil after intravenous and oral administration in healthy Chinese subjects
por: Yang, Haijing, et al.
Publicado: (2023)

Randomized, Open-Label Study of the Pharmacokinetics and Safety of Oral and Intravenous Administration of Omadacycline to Healthy Subjects
por: Sun, Haiying, et al.
Publicado: (2016)

Safety and Pharmacokinetics of the Aminomethylcycline Antibiotic Omadacycline Administered to Healthy Subjects in Oral Multiple-Dose Regimens
por: Bundrant, Lu Ann, et al.
Publicado: (2018)

Safety, tolerability, pharmacokinetics, and immunogenicity of an anti-SARS-CoV-2 monoclonal antibody HFB30132A after single dose intravenous administration in healthy Chinese subjects: a phase 1, randomized, double-blind, placebo-controlled study
por: Li, Shanshan, et al.
Publicado: (2023)

Study of GABA in Healthy Volunteers: Pharmacokinetics and Pharmacodynamics
por: Li, Junfeng, et al.
Publicado: (2015)

Pharmacokinetic-Pharmacodynamic Characterization of Omadacycline against Haemophilus influenzae Using a One-Compartment In Vitro Infection Model
por: VanScoy, Brian D., et al.
Publicado: (2020)

Comparison of Omadacycline and Tigecycline Pharmacokinetics in the Plasma, Epithelial Lining Fluid, and Alveolar Cells of Healthy Adult Subjects
por: Gotfried, Mark H., et al.
Publicado: (2017)

Dose adjustment not required for contezolid in patients with moderate hepatic impairment based on pharmacokinetic/pharmacodynamic analysis
por: Wu, Junzhen, et al.
Publicado: (2023)

Pharmacokinetics and Pharmacodynamics of Lisdexamfetamine Compared with D-Amphetamine in Healthy Subjects
por: Dolder, Patrick C., et al.
Publicado: (2017)

Pharmacokinetics and Safety of Doripenem in Healthy Chinese Subjects and Monte Carlo Dosing Simulations
por: Wang, Yu, et al.
Publicado: (2022)

Pharmacokinetics, Distribution, Metabolism, and Excretion of Omadacycline following a Single Intravenous or Oral Dose of (14)C-Omadacycline in Rats
por: Lin, Wen, et al.
Publicado: (2016)

Population Pharmacokinetic Analyses for Omadacycline Using Phase 1 and 3 Data
por: Lakota, Elizabeth A., et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Nemonoxacin in a Neutropenic Murine Lung Infection Model Against Streptococcus Pneumoniae
por: Li, Xin, et al.
Publicado: (2021)

A Randomized, Double‐Blind, Parallel‐Group, Phase 1 Clinical Trial Comparing the Pharmacokinetic, Safety, and Immunogenicity of the Biosimilar HS016 and the Originator Adalimumab in Chinese Healthy Male Subjects
por: Cao, Guoying, et al.
Publicado: (2020)

Pharmacokinetic/Pharmacodynamic Based Breakpoints of Polymyxin B for Bloodstream Infections Caused by Multidrug-Resistant Gram-Negative Pathogens
por: Bian, Xingchen, et al.
Publicado: (2022)

Single and Repeated Doses of EGb 761(®) do not Affect Pharmacokinetics or Pharmacodynamics of Rivaroxaban in Healthy Subjects
por: Hoerr, Robert, et al.
Publicado: (2022)

734. Modeling the Pharmacokinetics and Pharmacodynamics of Intravenous and Oral Omadacycline with and without a Loading Dose
por: Friedrich, Lawrence, et al.
Publicado: (2019)

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses Evaluating Omadacycline Dosing Regimens for the Treatment of Patients with Community-Acquired Bacterial Pneumonia Arising from Streptococcus pneumoniae and Haemophilus influenzae
por: Bhavnani, Sujata M., et al.
Publicado: (2023)

Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of CMAB807, a New Denosumab Biosimilar, in Healthy Chinese Subjects
por: Chen, Hanjing, et al.
Publicado: (2022)

An Open-Label Study of the Impact of Hepatic Impairment on the Pharmacokinetics and Safety of Single Oral and Intravenous Doses of Omadacycline
por: Kovacs, Steven J., et al.
Publicado: (2020)

Evaluation of Tolerability, Pharmacokinetics and Pharmacodynamics of Vicagrel, a Novel P2Y12 Antagonist, in Healthy Chinese Volunteers
por: Li, Xiaojiao, et al.
Publicado: (2018)

Editorial: Pharmacokinetics and Pharmacodynamics of Pre-Exposure Prophylaxis Against HIV
por: von Kleist, Max, et al.
Publicado: (2020)

Pharmacodynamics and Pharmacokinetics of Fluticasone Furoate/Vilanterol in Healthy Chinese Subjects
por: Chen, Xia, et al.
Publicado: (2015)

Population Pharmacokinetic/Pharmacodynamic Model-Guided Dosing Optimization of a Novel Sedative HR7056 in Chinese Healthy Subjects
por: Zhou, Ying, et al.
Publicado: (2018)

Gender differences in pharmacokinetics and pharmacodynamics of methadone substitution therapy
por: Graziani, Manuela, et al.
Publicado: (2015)

Gene Polymorphisms Affecting the Pharmacokinetics and Pharmacodynamics of Donepezil Efficacy
por: Lu, Jin, et al.
Publicado: (2020)

Comorbid epilepsy and depression—pharmacokinetic and pharmacodynamic drug interactions
por: Miziak, Barbara, et al.
Publicado: (2022)

Pharmacokinetic and pharmacodynamic similarity evaluation between an insulin glargine biosimilar product and Lantus(®) in healthy subjects: Pharmacokinetic parameters of both parent insulin glargine and M1 were used as endpoints
por: Wang, Yiya, et al.
Publicado: (2022)

Corrigendum: Population Pharmacokinetic/Pharmacodynamic Model-Guided Dosing Optimization of a Novel Sedative HR7056 in Chinese Healthy Subjects
por: Zhou, Ying, et al.
Publicado: (2019)

Pharmacokinetics/pharmacodynamics of polymyxin B in patients with bloodstream infection caused by carbapenem-resistant Klebsiella pneumoniae
por: Yu, Zhenwei, et al.
Publicado: (2022)

Insights into the pharmacodynamics and pharmacokinetics of meldonium after exposure to acute high altitude
por: Liu, Fengying, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cooeq0icos333rbgph3ermeub5